India’s Pharmaceutical Sector: Scale and Global Significance

India’s pharmaceutical industry, valued at USD 45 billion in 2023 (IBEF), ranks as the third-largest globally by volume (UN Comtrade, 2023). It accounts for approximately 20% of the global generic medicines supply by volume (WHO, 2023) and supplies over 50% of global vaccine demand. With over 60,000 manufacturing units and 3,000 drug companies (Department of Pharmaceuticals, 2023), India is a critical node in global healthcare supply chains. Exports reached USD 24.44 billion in FY 2022-23, growing 17.5% year-on-year (Pharmexcil Annual Report), underscoring India’s role as a global pharmaceutical powerhouse. However, the sector faces challenges in innovation and quality control that could impact its future leadership.

Legal and Regulatory Framework Governing Pharmaceuticals in India

The Drugs and Cosmetics Act, 1940 regulates import, manufacture, and distribution of drugs with key provisions in Sections 3 (definitions), 18 (licensing), and 33 (penalties). The Pharmacy Act, 1948 governs pharmacy education and practice standards. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 restricts misleading drug advertisements. The National Pharmaceutical Pricing Authority (NPPA), established under the Essential Commodities Act, 1955, controls drug prices to ensure affordability. Landmark Supreme Court rulings like Novartis AG vs. Union of India (2013) upheld Section 3(d) of the Patents Act, 1970, restricting patentability of incremental pharmaceutical innovations to protect generic competition.

• CDSCO functions as the national regulatory authority ensuring drug quality and safety.
• NPPA enforces price caps on essential medicines, balancing industry and public health interests.
• Pharmexcil promotes export growth and market diversification.
• Department of Pharmaceuticals formulates policies and implements schemes like the Production Linked Incentive (PLI).
• ICMR and BIRAC support R&D and biotech innovation.

Economic Dimensions and Market Dynamics

India's pharmaceutical industry contributes 1.72% to the national GDP (Economic Survey 2023-24). The sector’s domestic market is projected to reach USD 65 billion by 2026 (IBEF), driven by rising healthcare demand and government initiatives. Exports of USD 24.44 billion in FY 2022-23 position India as the third-largest global exporter (Pharmexcil). The government allocated INR 3,100 crore under the PLI scheme in 2023 to incentivize domestic manufacturing, targeting INR 13,000 crore investment over five years (Ministry of Chemicals and Fertilizers, 2023). India dominates 62% of the global antiretroviral drug market (UNAIDS, 2023), reflecting its strategic role in global disease control.

• Over 60,000 manufacturing units ensure scale but raise quality control challenges.
• R&D expenditure is 8% of industry turnover, lagging behind the US (15%) and China (12%) (IBEF, 2023).
• The sector’s focus remains on generics, with limited patented drug development.

Comparative Analysis: India vs. China in Pharmaceutical Innovation and Policy

Critical Challenges: Innovation Deficit and Quality Control

India’s pharmaceutical sector’s reliance on generic drug manufacturing constrains its ability to innovate novel drugs and capture higher value in global pharmaceutical value chains. The R&D expenditure of 8% is insufficient compared to global competitors, limiting breakthroughs in patented medicines. Quality control issues, including regulatory compliance lapses, have occasionally led to import bans by the US FDA, denting India’s export credibility. The regulatory framework, while robust, requires strengthening in post-market surveillance and incentivizing high-end research.

• Limited patented drug development restricts global leadership beyond generics.
• Quality control lapses impact international market access.
• Need to enhance regulatory capacity of CDSCO and harmonize standards with global benchmarks.

Significance and Way Forward

India’s pharmaceutical sector is indispensable to global healthcare, especially in affordable generics and vaccines. Sustaining this leadership requires increased R&D investment, fostering innovation ecosystems, and improving regulatory enforcement. Policy measures should focus on expanding PLI incentives to biotech startups, strengthening ICMR-BIRAC collaboration for novel drug discovery, and enhancing CDSCO’s capacity for faster, transparent approvals. Addressing quality control issues is critical to maintaining export growth and international trust. Balancing affordability with innovation will define India’s future role in global pharmaceutical leadership.

• Increase R&D intensity to at least 12-15% of turnover to compete globally.
• Expand PLI scheme scope to include biotech and patented drug development.
• Strengthen CDSCO’s regulatory framework and align with WHO prequalification standards.
• Promote public-private partnerships for innovation and clinical trials.
• Enhance training and infrastructure for quality assurance in manufacturing units.